Gain Therapeutics, Inc.’s GANX share price has surged by 13.74%, which has investors questioning if this is right time to sell.

and followed with two other licensing deals involving a pair of gene therapies for GM1 and GM2 gangliosidosis – AXO-AAV-GM1 and AXO-AAV-GM2 – from the University of Massachusetts. It also ...

The Brazilian project will focus on six programmes, targeting GM1 gangliosidosis (GM1), Krabbe disease, metachromatic leukodystrophy (MLD), and three unnamed programmes. The funding will be used ...

Ophthalmology: ptosis (mitochondrial disorders, Menkes syndrome), retinal degeneration (grey matter disease), optic atrophy (white matter disease), cherry-red spots (GM1/2 gangliosidosis, Krabbe ...

The GM2 gangliosidoses are a group of heritable neurodegenerative disorders caused by excessive accumulation of the ganglioside GM2 owing to deficiency in beta-hexosaminidase activity. Tay-Sachs ...

Current paediatric standard-of-care for galactosemia is a lactose-free diet. Image credit: Shutterstock / Photoongraphy. Nearly three months after an experimental treatment for classic galactosemia ...

After hours: March 17 at 7:47:38 PM EDT Loading Chart for GANX ...

We present a patient with clinical features consistent with BBE and positive anti-GM1 and anti-GD1a antibodies. A diagnostic approach to the acutely unwell patient with brainstem encephalitis is ...